A major breakthrough in the fight against COVID-19 has been announced by the World Health Organization (WHO). The organization has approved the use of a new drug, called Sotrovimab, for emergency use in treating patients with mild to moderate cases of the virus.
Sotrovimab, developed by the pharmaceutical company GlaxoSmithKline, is a monoclonal antibody therapy that works by targeting the spike protein of the coronavirus. This protein is responsible for the virus’s ability to enter and infect human cells. By binding to the spike protein, Sotrovimab prevents the virus from replicating and spreading throughout the body.
The drug has shown promising results in clinical trials, with a 79% reduction in hospitalizations and deaths among high-risk patients. It has also been found to be effective against the new variants of the virus, including the highly transmissible Delta variant.
Dr. Mariângela Simão, WHO Assistant Director-General for Access to Medicines and Health Products, stated that the approval of Sotrovimab is a significant step in the fight against COVID-19. She emphasized the importance of having a variety of treatment options available to combat the virus and reduce the burden on healthcare systems.
The emergency use authorization of Sotrovimab by the WHO means that the drug can now be used in countries that do not have their own regulatory processes in place. This will help to ensure that patients in low- and middle-income countries have access to life-saving treatments.
However, the WHO also stressed the importance of continuing to follow public health measures, such as wearing masks and practicing social distancing, to prevent the spread of the virus. The organization also urged countries to ramp up their vaccination efforts to further control the pandemic.
Sotrovimab joins a growing list of treatments that have been approved for emergency use by the WHO, including the antiviral drug Remdesivir and the steroid Dexamethasone. With the addition of Sotrovimab, healthcare professionals now have another tool in their arsenal to combat the ongoing global health crisis.
The approval of Sotrovimab by the WHO is a significant development in the fight against COVID-19. It offers hope for patients with mild to moderate cases of the virus and provides another option for healthcare professionals to treat and manage the disease. However, it is crucial to continue following public health measures and increasing vaccination efforts to ultimately bring an end to the pandemic.
